Targeting enhancer of zeste homolog 2: A novel therapeutic approach for head and neck cancer

Head and neck cancer represents a diverse group of malignancies primarily affecting the oral cavity, pharynx, and larynx. Understanding the molecular mechanisms underlying head and neck cancer progression is crucial for developing targeted therapies. In the last years, great attention has been given to the role of Enhancer of Zeste Homolog 2 (EZH2), a key component of the Polycomb Repressive Complex 2 (PRC2), in cancer. EZH2 regulates critical pathways involved in cell proliferation, differentiation, and survival, which can contribute to the tumor microenvironment's dynamics. EZH2 overexpression has been implicated in the progression and metastasis of various cancers, including head and neck cancer, suggesting it could be used as a potential biomarker. EZH2 inhibitors are being explored in preclinical and clinical settings, aiming to enhance the efficacy of existing treatments. Understanding the role of EZH2 in head and neck cancer not only provides insights into the disease's biology but also paves the way for innovative therapeutic strategies that could improve patient outcomes. Thus, our review aims to deeply investigate the function of EZH2 in the pathological context of head and neck cancer, focusing on its potential as a molecular target for emerging therapies.